An Investigation on the prioritization scheme in the treatment of Mild-to-moderate depressive Disorder by Acupuncture: A Randomized Controlled Clinical Trail

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001540

Enrollment

Unknown

Registered

2011-08-20

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild-to-moderate depressive Disorder

Interventions

Group of electro-acupuncture combined with Seroxat:The patients receive a 30-minute electro-acupuncture treatment, applied once another day, total 3 times a week over 6 consecutive weeks. Meanwhile, S

Group of manual acupuncture:The patients receive a 30-minute manual acupuncture treatment, applied once another day, total 3 times a week over 6 consecutive weeks.

Group of electro-acupuncture:The patients receive a 30-minute electro-acupuncture treatment, applied once another day, total 3 times a week over 6 consecutive weeks.

Group of Seroxat:Seroxat is administered as a dose of 10mg a day for the fist 2days, then increased to 20mg day, the total treatment is over 6 consecutive weeks.

Group of manual acupuncture combined with Seroxat:The patients receive a 30-minute manual acupuncture treatment, applied once another day, total 3 times a week over 6 consecutive weeks. Meanwhile, Ser

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) been diagnosed as Mild-to-moderate depressive Disorder with the "International Classification of Diseases and diagnostic criteria", except bipolar depression; (2) the total score of 17-items Hamilton Depression Rating Scale (HAMD-17) more than 17; (3) both male and female, 18 to 60 years old; (4) sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) received other clinical trails during the last 4 weeks; (2) taking or had taken antidepressant agent during the last 2 weeks; (3) taking antiarhythmic agent, hypoglycemic agent and tryptophan; (4) pregnant women and breast-feeding women; (5) serious uncontrolled medical conditions of other system; (6) a primary diagnosis other cerebrosis; (7) Current active suicidal potential necessitating immediate treatment.

Design outcomes

Primary

Measure	Time frame
Deducted rate of HAMD-17 score;	—

Secondary

Measure	Time frame
Scores of HAMD-17;Scores of SDS (Selfrating Depression Scale);Scores of SERS (Rating Scale for Side Effects;	—

Contacts

Public ContactHuang Yong

13719189644@qq.com+86 13719189644

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026